Marietta, GA
Ketamine Therapy clinics in Marietta
Ketamine therapy in Marietta is delivered through psychiatry-led clinics, anesthesia-run infusion centers, and ketamine-assisted psychotherapy practices, with hospital referrals often tied to Wellstar Kennestone and Northside Cherokee. Demand reflects a suburban Cobb County family and retiree population and an active local market for treatment-resistant depression, PTSD, and chronic pain.
The strongest evidence supports intranasal esketamine (Spravato, FDA-approved for treatment-resistant depression) and intravenous racemic ketamine (off-label, substantial supporting evidence). Clinics in Marietta, Georgia also offer intramuscular, sublingual, and at-home oral lozenge protocols, with weaker evidence and variable safety oversight. Georgia medical board delegation and medspa oversight rules shapes which clinics can operate as cash-pay versus insurance-eligible.
With ketamine clinics on Regenerated.com in Marietta, patients can compare whether the clinic offers psychiatric evaluation, anesthesia monitoring during infusion, and structured preparation and integration.
Invictus Clinic - Ketamine Treatment Atlanta
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- Ketamine Therapy
- Migraine Treatment
Regulatory context
A note on Georgia's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Georgia Controlled Substances Act (O.C.G.A. 16-13)
Mirrors federal scheduling; no therapeutic access framework for psilocybin or MDMA.
Georgia enforces federal scheduling. The Georgia Composite Medical Board investigates prescriber conduct, including ketamine prescribing and office-based anesthesia. DEA enforcement on ketamine clinics focuses on diversion, compounding sources, and Ryan Haight Act telehealth compliance. Georgia's PDMP requires controlled substance reporting.